In an effort to further extend the number of targets for development of antiretroviral agents, we have used an in vitro integrase assay to investigate a variety of MATERIALS AND METHODS Materials. HIV-1 integrase protein (3.5 pmol per reaction), produced via an Escherichia coli expression vector as described (13), was obtained from R. Craigie (Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases) and stored at -70°C in 1 M NaCl/20 mM Hepes, pH 7.6/1 mM EDTA/1 mM dithiothreitol/20% glycerol (wt/vol). Caffeic acid phenethyl ester (CAPE) was brought to our attention by Dezider Grunberger (Columbia University, New York), who supplied the compound. Doxorubicin, 5-iminodaunorubicin, mitoxantrone, ellipticine, ellipticinium, 9-aminoacridine, amsacrine, ditercalinium, ethidium, camptothecin, 9-aminocamptothecin, 10,11-methylenedioxycamptothecin, etoposide (VP-16), teniposide (VM-26), and quercetin were obtained through the Developmental Therapeutics Program, National Cancer Institute. Hydroxyrubicin and adriamycinone were obtained through Waldemar Priebe (M. D. Anderson Hospital, Houston). Naphthoquinone, 5,8-dihydroxy-1,4-naphthoquinone, 5-hydroxy-1,4-naphthoquinone, and dihydroxyanthraquinone were purchased from Aldrich. Chloroquine, primaquine, quinacrine, and amodiaquine were obtained through Sigma. Hydroxychloroquine was from SterlingWinthrop Research Institute. Mefloquine was from Hoffmann-La Roche.
5,8-dihydroxy-1,4-naphthoquinone, and caffeic acid phenethyl ester inhibit the integrase. Caffeic acid phenethyl ester was the only compound that inhibited the integration step to a substantially greater degree than the initial cleavage step of the enzyme. A model of 5,8-dihydroxy-1,4-naphthoquinone interaction with the zinc finger region of the retroviral integrase protein is proposed.
Although human immunodeficiency virus (HIV) integrasemediated integration of HIV DNA into the host genome is essential to the virus life cycle, to date pharmacologic antiretroviral research has neglected this enzyme, focusing principally on agents that inhibit other virally encoded enzymes, such as HIV reverse transcriptase or HIV protease (1) . In vitro systems using oligonucleotide substrates and purified integrase protein have been invaluable for investigating the DNA substrate requirements and chemical mechanisms of the reactions catalyzed by the HIV integrase (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . The development of an in vitro assay of integrase function now permits rapid testing of a large number of compounds as potential inhibitors of the HIV integrase. We report here an investigation of the effects of many such inhibitors on the cleavage and strand-transfer reactions; to our knowledge the only previous study is the demonstration (12) Gilbert loading buffer to each 16-,ul sample. Subsequently 4 Al of each sample was run on a 20% denaturing polyacrylamide gel in lx TBE buffer (TBE is 90 mM Tris/64.6 mM boric acid/2.5 mM EDTA, pH 8.3). Gels were dried, and autoradiography was done by using Kodak XAR-2 film.
Quantitation. Dried gels were analyzed by using a Betascope 603 blot analyzer (Betagen, Waltham, MA). Radioactivity was counted in the 19-mer cleavage band, the larger integration bands (to avoid interference from the 21-mer origin band) and the lane total. Percent inhibition was calculated by the following equation: IC50 is the concentration of compound producing 50% inhibition. IC50 values were calculated from a sigmoid model by using the formula:
where x is the concentration of compound tested, y is percent inhibition, and n is the Hill coefficient and was set at 1.2, a mean. 'i, , step involves nucleolytic cleavage of two bases from the 3' end. Subsequently, these recessed 3' ends arejoined, through a strand-transfer reaction, to the 5' end of an integraseinduced break in an identical second oligonucleotide, which serves as the target DNA. Reaction products were separated by electrophoresis on a 20% denaturing acrylamide gel. A ,-emission detector was used to quantitate dried gels. Results were expressed as percentage inhibition of the nucleolytic cleavage and integration products. Typical results for HIV integrase in the absence of inhibitor were 12-15% nucleolytic cleavage and 2-5% strand-transfer/integration products in a reaction where the molar ratio of integrase to DNA was 10:1. Our initial goal, to test whether DNA topoisomerase inhibition correlated with integrase inhibition, was prompted by reports of antiretroviral activity of camptothecins (14) , as well as by analogies between the mechanisms of the integrase and topoisomerase II (top2). These analogies include the production of 5' overhangs in DNA, the ability to recombine cleaved double-stranded DNA, and the possibility of a covalently linked intermediate (15, 16) . Doxorubicin (compound 1), a potent top2 inhibitor and a clinically important antitumor agent, was among the most potent inhibitors of HIV integrase-mediated DNA cleavage and integration tested (Figs. 2-5, Table 1 ). Several analogs of doxorubicin were analyzed to evaluate the importance of DNA binding. As this binding is stabilized by the cationic charge of the sugar amino group, replacement of this amino group with a hydroxy group, as in hydroxyrubicin (compound 2), would be expected to reduce DNA binding (Table 1) . Hydroxyrubicin inhibited the integrase with 12-to 16-fold less potency than did doxorubicin (Figs. 2-5, Table 1 ). However, the inhibition by hydroxyrubicin was similar to that produced by 5-iminodaunorubicin (compound 3) (Figs. 2-5, Table 1 ) which retains the sugar amino group and binds to DNA with affinity similar to doxorubicin. Doxorubicin, hydroxyrubicin, and 5-iminodaunorubicin all inhibit top2 and possess antitumor activity. Doxorubicin aglycone (compound 4), which lacks the sugar moiety, was found by DNA-supercoil-relaxation assays to bind DNA very weakly and inhibited HIV integrase cleavage detectably only at 100 ,uM (39o inhibition of cleavage) (Figs. 2-5 , Table 1 ).
RESULTS AND DISCUSSION
Several other types of DNA-intercalating top2 inhibitors were effective inhibitors of HIV integrase, including mitoxantrone (compound 5), ellipticines, and their related derivative intoplicine (RP-60475, compounds 10-12) (Figs. 2-5 , Table 1 ). However, amsacrine, another DNA-intercalating top2 inhibitor, had no detectable effect on the HIV integrase. Quercetin, which is a weak DNA intercalator and a weak top2 inhibitor, was a potent HIV integrase inhibitor ( Table 1 , and structures are shown in Fig. 5 .
In addition, both of the epipodophyllotoxins, etoposide (VP-16) and teniposide (VM-26), which do not bind DNA detectably, but block top2 complexes, possibly by a base-stacking mechanism (32), were inactive against the integrase. The DNA topoisomerase I inhibitor camptothecin and its two more potent analogs were also inactive in the integrase assay (Table 1 quinacrine, a stronger intercalator, was inactive (Table 1) . Similarly, other types of DNA binders, including polyamines and minor-groove binders such as spermine, spermidine, and distamycin, did not inhibit the HIV integrase. Also without effect was the DNA intercalator 9-aminoacridine (compound 13, Fig. 2, Table 1 ). Primaquine, a chloroquine relative having little or no affinity for DNA, was as effective as chloroquine in the integrase assay. Thus, as with inhibition of top2, there is no strong correlation between DNA-binding affinity of DNA intercalators and enzyme inhibition. The inactivity ofcertain DNA intercalators may be from a number of confounding factors, including local differences in the mode of intercalation such as minor-or major-groove binding, residence time, or sequence selectivity. Although many of these compounds have been tested for sequence selectivity in various systems, the literature is incomplete and at times contradictory. Thus, as with top2 inhibition, when the correlation between integrase inhibition and DNA binding was evaluated among a broad range of compounds, there were marked discrepancies. Therefore, enzyme inhibition may involve direct interaction of drug with enzyme in addition to DNA intercalation.
Several classes of non-DNA binders were then tested.
Substituted 1,4-naphthoquinones were examined to test whether a moiety common to the structures of doxorubicin and mitoxantrone could be a "master key" responsible for The inhibition of HIV integrase by the double-hydroxylated (DHNQ), not the single (5-hydroxynaphthoquinone) or nonhydroxylated naphthoquinone (Fig. 4) , suggests the pos-sibility of DHNQ acting by binding to a zinc finger structure in the HIV integrase. Point-mutation analyses of integrase function by Engleman and Craigie (33, 35, 36) indicate that mutation of the histidines (His-12 and His-16) and cysteines (Cys-40 and Cys-43) of the His-Cys zinc finger region impair cleavage processing and integration while not affecting the reverse or "disintegration" reaction. Thus, this region of the protein appears important for the cleavage and integration steps of the HIV integrase reaction and may be involved in production of a multimeric state ofintegrase required for both the cleavage and integration steps but not for the disintegration reaction. DHNQ consists of juxtaposed phenolic hydroxy and keto groups that are effective chelators of divalent metal ions. Therefore, DHNQ may displace the imidazole ligands of the zinc finger contributed by the two histidine residues (37) . Binding to the His-Cys zinc finger region of the integrase would lead to compromised enzyme activity. If a zinc finger model proves to be correct and essential to integrase function, it may be possible to specifically design compounds that would bind to this region.
Although the in vitro assay used in this study has been valuable to the understanding of integrase molecular pharmacology, exploiting this information to develop agents active in preventing HIV replication in intact cells will require development of a simple and safe assay by which the rate of viral integration in intact cells can be measured.
